Live Expert Q&A: Strategies for Success in Atopic Dermatitis Care is organized by Prime Education, LLC and will be held on Jan 16, 2020.
Physicians, Nurse Practitioners, Pharmacists, and Nurses.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Physician Credit Designation Statement:
PRIME® designates this Live activity for a maximum of 0.5 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Accreditation Statement:
Nurse Practitioner LogoPRIME® is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour of continuing education (which includes 0 hours of pharmacology).
Pharmacist Accreditation Statement:
This Application-based activity has been approved for 0.5 contact hour (0.05 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-19-075-L01-P. Pharmacy CE credits can be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (firstname.lastname@example.org).
Nurse Accreditation Statement:
PRIME® designates this activity for 0.5 contact hour.
• The latest clinical evidence and how it's shaping AD assessment, treatment, and management
• Pioneers in the field that are building bridges between specialty and primary care teams to optimize shared management of AD
• Apply validated methods for atopic dermatitis (AD) diagnosis and disease severity assessment in adult and pediatric patients
• Evaluate current efficacy and safety evidence on new therapies for patients with moderate to severe AD
• Implement telehealth and other strategies to communicate with AD specialists to ensure that patients with moderate to severe disease receive needed therapies
• Incorporate methods to support patients with AD in accessing and adhering to needed therapies